XML 75 R57.htm IDEA: XBRL DOCUMENT
v3.25.2

Liability Related to Sale of Future Royalties - Liability Related to Sale of Future Royalties (Details) - Royalty Purchase Agreement [Member] $ in Thousands | 6 Months Ended
--- | ---
Jun. 30, 2025 USD ($)
Royalty Revenue Monetization [Abstract] |
Liability related to sale of future royalties, net | $ 542,212
Royalty payments to Royalty Pharma | (24,894)
Interest expense related to sale of future royalties | 37,165
Amortization of issuance costs related to sale of future royalties | 305
Liability related to sale of future royalties, net | 554,788
Liability related to sale of future royalties, net - Non-current | 541,205
Other Current Liabilities [Member] |
Royalty Revenue Monetization [Abstract] |
Less: Current portion | $ (13,583)

X
- Definition Amount of amortization expense attributable to the sale of future royalties. + References No definition available. + Details
Name: | ions_AmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of interest expense using the effective interest rate method related to the sale of future royalties. + References No definition available. + Details
Name: | ions_InterestExpenseRelatedToSaleOfFutureRoyalties
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, after accumulated amortization, of the unamortized liability related to the sale of future royalties, pursuant to a royalty purchase agreement, that the Company is entitled to receive under collaboration agreements with Biogen and Novartis. The balance will be amortized over the estimated life of the arrangement using the effective interest rate method. + References No definition available. + Details
Name: | ions_LiabilityRelatedToSaleOfFutureRoyaltiesNet
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, after accumulated amortization, of the unamortized liability related to the sale of future royalties, pursuant to a royalty purchase agreement, that the Company is entitled to receive under collaboration agreements with Biogen and Novartis. The balance will be amortized over the estimated life of the arrangement using the effective interest rate method. Used to reflect the current portion of the liability (due within one year or within the normal operating cycle if longer). + References No definition available. + Details
Name: | ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetCurrent
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, after accumulated amortization, of the unamortized liability related to the sale of future royalties, pursuant to a royalty purchase agreement, that the Company is entitled to receive under collaboration agreements with Biogen and Novartis. The balance will be amortized over the estimated life of the arrangement using the effective interest rate method. Used to reflect the noncurrent portion of the liability (due after one year or beyond the operating cycle if longer). + References No definition available. + Details
Name: | ions_LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of royalty payments made during the period under a royalty purchase agreement. + References No definition available. + Details
Name: | ions_RoyaltyPayments
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_RoyaltyPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |